178 related articles for article (PubMed ID: 31949019)
21. Platelet membrane lipid rafts protein composition varies following GPVI and CLEC-2 receptors activation.
Izquierdo I; Barrachina MN; Hermida-Nogueira L; Casas V; Eble JA; Carrascal M; Abián J; García Á
J Proteomics; 2019 Mar; 195():88-97. PubMed ID: 30677554
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine phosphorylation on spleen tyrosine kinase (Syk) is differentially regulated in human and murine platelets by protein kinase C isoforms.
Buitrago L; Bhavanasi D; Dangelmaier C; Manne BK; Badolia R; Borgognone A; Tsygankov AY; McKenzie SE; Kunapuli SP
J Biol Chem; 2013 Oct; 288(40):29160-9. PubMed ID: 23960082
[TBL] [Abstract][Full Text] [Related]
23. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
24. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
[TBL] [Abstract][Full Text] [Related]
25. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets.
Hughes CE; Finney BA; Koentgen F; Lowe KL; Watson SP
Blood; 2015 Jan; 125(1):144-54. PubMed ID: 25352128
[TBL] [Abstract][Full Text] [Related]
26. Heme activates platelets and exacerbates rhabdomyolysis-induced acute kidney injury via CLEC-2 and GPVI/FcRγ.
Oishi S; Tsukiji N; Otake S; Oishi N; Sasaki T; Shirai T; Yoshikawa Y; Takano K; Shinmori H; Inukai T; Kondo T; Suzuki-Inoue K
Blood Adv; 2021 Apr; 5(7):2017-2026. PubMed ID: 33843987
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the GPVI inhibitors losartan and honokiol.
Onselaer MB; Nagy M; Pallini C; Pike JA; Perrella G; Quintanilla LG; Eble JA; Poulter NS; Heemskerk JWM; Watson SP
Platelets; 2020; 31(2):187-197. PubMed ID: 30849265
[TBL] [Abstract][Full Text] [Related]
28. CLEC-2 expression is maintained on activated platelets and on platelet microparticles.
Gitz E; Pollitt AY; Gitz-Francois JJ; Alshehri O; Mori J; Montague S; Nash GB; Douglas MR; Gardiner EE; Andrews RK; Buckley CD; Harrison P; Watson SP
Blood; 2014 Oct; 124(14):2262-70. PubMed ID: 25150298
[TBL] [Abstract][Full Text] [Related]
29. Phosphorylation on Syk Y342 is important for both ITAM and hemITAM signaling in platelets.
Kostyak JC; Mauri B; Dangelmaier C; Vari HR; Patel A; Wright M; Reddy H; Tsygankov AY; Kunapuli SP
J Biol Chem; 2022 Aug; 298(8):102189. PubMed ID: 35753354
[TBL] [Abstract][Full Text] [Related]
30. Development of a pharmacodynamic assay based on PLCγ2 phosphorylation for quantifying spleen tyrosine kinase (SYK)-Bruton's tyrosine kinase (BTK) signaling.
Hsu J; Zhang J; Kitson C; Tan SL; Narula S; DeMartino JA; Liao C
J Biomol Screen; 2013 Sep; 18(8):890-8. PubMed ID: 23704133
[TBL] [Abstract][Full Text] [Related]
31. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.
Smith CW; Harbi MH; Garcia-Quintanilla L; Rookes K; Brown H; Poulter NS; Watson SP; Nicolson PLR; Thomas MR
J Thromb Haemost; 2022 Dec; 20(12):2939-2952. PubMed ID: 36239466
[TBL] [Abstract][Full Text] [Related]
32. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
[TBL] [Abstract][Full Text] [Related]
33. Differential roles for the adapters Gads and LAT in platelet activation by GPVI and CLEC-2.
Hughes CE; Auger JM; McGlade J; Eble JA; Pearce AC; Watson SP
J Thromb Haemost; 2008 Dec; 6(12):2152-9. PubMed ID: 18826392
[TBL] [Abstract][Full Text] [Related]
34. Tec regulates platelet activation by GPVI in the absence of Btk.
Atkinson BT; Ellmeier W; Watson SP
Blood; 2003 Nov; 102(10):3592-9. PubMed ID: 12842985
[TBL] [Abstract][Full Text] [Related]
35. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.
Navarro-Núñez L; Pollitt AY; Lowe K; Latif A; Nash GB; Watson SP
Thromb Haemost; 2015 May; 113(5):1109-20. PubMed ID: 25694214
[TBL] [Abstract][Full Text] [Related]
36. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands.
Alshehri OM; Montague S; Watson S; Carter P; Sarker N; Manne BK; Miller JL; Herr AB; Pollitt AY; O'Callaghan CA; Kunapuli S; Arman M; Hughes CE; Watson SP
Biochem J; 2015 Jun; 468(3):459-73. PubMed ID: 25849538
[TBL] [Abstract][Full Text] [Related]
37. CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP.
Borgognone A; Navarro-Núñez L; Correia JN; Pollitt AY; Thomas SG; Eble JA; Pulcinelli FM; Madhani M; Watson SP
J Thromb Haemost; 2014 Apr; 12(4):550-9. PubMed ID: 24460629
[TBL] [Abstract][Full Text] [Related]
38. Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Busygina K; Denzinger V; Bernlochner I; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Aug; 119(8):1212-1221. PubMed ID: 31087308
[TBL] [Abstract][Full Text] [Related]
39. [CLEC-2 induced signalling in blood platelets].
Martyanov AA; Kaneva VN; Panteleev MA; Sveshnikova AN
Biomed Khim; 2018 Sep; 64(5):387-396. PubMed ID: 30378555
[TBL] [Abstract][Full Text] [Related]
40. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
Oda A; Ikeda Y; Ochs HD; Druker BJ; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte ON; Wahl MI
Blood; 2000 Mar; 95(5):1663-70. PubMed ID: 10688822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
